Trial NCT00354107

View at ClinicalTrials.gov 
Org. Study IDs: NCI-2009-00407
Secondary IDs: ANHL06P1 CDR0000486425 COG-ANHL06P1 NCI-2009-00407 U10CA098543

Last trial update was posted on 2018-03-14

MeSH Interventions

Antibodies Antibodies, Monoclonal Brentuximab Vedotin Carboplatin Cytarabine Etoposide Etoposide phosphate Hydrocortisone Hydrocortisone 17-butyrate 21-propionate Hydrocortisone acetate Hydrocortisone hemisuccinate Ifosfamide Methotrexate

MeSH Conditions

Lymphoma Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Recurrence

Other Conditions

Anaplastic Large Cell Lymphoma Recurrent Childhood Anaplastic Large Cell Lymphoma

Stopping Reasons

N/A

Limitations And Caveats

Number of participants analyzed = 4. One patient was not evaluable for response. The Secondary Outcome measures will never be reported as data were not collected to assess these study aims.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID